Article

RP has edge over radiotherapy in low-risk patients

Orlando, FL-The relative efficacy of radical prostatectomy andexternal beam radiation therapy for treating clinically localized prostatecancer diagnosed during the PSA era appears to depend on patient risk, accordingto the results of a retrospective study.

Related Videos
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
1 expert in this video
Related Content
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
April 17th 2025

NMIBC Clinical Forums highlight novel therapies and treatment strategies

Urology Times staff
Two recent Clinical Forum discussions sought to examine how emerging therapeutic options and evolving treatment standards in non–muscle invasive bladder cancer affect clinical practices and patient outcomes.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Gene variant associated with increased risk of BPH
April 16th 2025

Gene variant associated with increased risk of BPH

Hannah Clarke
Data showed a significant association between the C allele of the SNP-765G>C of the PTGS2 gene and BPH.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
3d rendered medically accurate illustration of prostate cancer | Image Credit: @ Sebastian Kaulitzki - stock.adobe.com
April 15th 2025

Dose expansion begins in phase 1/2 trial of 67Cu-SAR-bisPSMA in mCRPC

Hannah Clarke
The first patient in the trial will be receiving 67Cu-SAR-bisPSMA in combination with enzalutamide.
FDA approval sought for Anktiva in papillary NMIBC
April 15th 2025

FDA approval sought for Anktiva in papillary NMIBC

Hannah Clarke
The sBLA is supported by data from cohort B of the pivotal QUILT-3.032 trial.
© 2025 MJH Life Sciences

All rights reserved.